Composite MACE endpoints were CV death, nonfatal MI, and nonfatal stroke.1
In adult patients with type 2 diabetes and established CVD, for the composite primary endpoint
After 2 years, Ozempic® significantly reduced the risk of potentially life-altering CV events (MACE)1,a
Major adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
aStandards of care included but were not limited to oral antidiabetic treatments, insulin, antihypertensives, diuretics, lipid-lowering therapies, and antithrombotic medications.
bEstimated cumulative risk of MACE at Week 104 was 6.2% with Ozempic® and 8.4% with placebo.3
ARR=absolute risk reduction; CV=cardiovascular; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; MACE=major adverse cardiovascular events; MI=myocardial infarction; NNT=number needed to treat; RRR=relative risk reduction.
Help patients realize the potential with Ozempic®
SUSTAIN 6—a 2‑year CVOT for Ozempic®2
Study design: 2-year, randomized, multinational, placebo-controlled, double-blind cardiovascular outcomes trial designed to assess noninferiority of Ozempic® vs placebo, both in addition to standard of care, for time to first MACE using a risk margin of 1.3.
Patients: A total of 3297 adult patients with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease were randomized to once-weekly Ozempic® 0.5 mg (n=826), once-weekly Ozempic® 1 mg (n=822), or placebo (n=1649), all in addition to standard of care treatments for diabetes and CVD such as oral antidiabetic treatments, insulin, antihypertensives, diuretics, lipid-lowering therapies, and antithrombotic medications at investigator discretion.
Primary endpoint: Time from randomization to first occurrence of a 3-part composite MACE defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.